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METHODS: We carried out a retrospective study of prognosis in Scottish patients diagnosed with cancer within 5 years after a venous
thromboembolism (VTE).
RESULTS AND CONCLUSIONS: Prognosis was significantly poorer if a VTE occurred up to 2 years before cancer diagnosis, most notably if
the cancer was diagnosed in the 6 months after a VTE.
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Trousseau first described an association between malignancy and
venous thromboembolism (VTE) more than a 100 years ago
(Trousseau, 1872), since which time it has become clear that
malignancy is a risk factor for VTE. More recently, several large
retrospective studies have shown an increased risk of cancer after a
diagnosis of idiopathic VTE, with standardised incidence ratios of
3–4.2 within the first 6 months (Nordstrom et al, 1994; Sorensen
et al, 1998; Murchison et al, 2004). The length of time for which
increased risk can be shown varies and we have shown a persistent,
although declining, risk up to 2 years from VTE diagnosis
(Murchison et al, 2004). Those with secondary VTE do not seem
to be at a similar risk of future malignancy (Prandoni et al, 1992;
Bastounis et al, 1996). In view of this increased risk, there has been
an interest in screening patients with idiopathic VTE for occult
malignancy. Initial retrospective studies in patients with idiopathic
deep vein thrombosis (DVT) suggested that most occult malig-
nancy could be detected by routine evaluation (Nordstrom
et al, 1994; Cornuz et al, 1996). However, more recent prospective
studies advocate a more intensive investigative approach (Monreal
et al, 2004; Piccioli et al, 2004).
Relatively little is known about the impact that a preceding VTE
has on the prognosis of subsequent malignancy, and this may well
inform the screening debate. A Danish registry study reported that
patients diagnosed with cancer during their admission for VTE
had a 1-year survival rate of 12% compared with 36% in the
control group of cancer patients without preceding VTE; 1-year
survival rates were also poorer in those diagnosed with cancer in
the year after a VTE (Sorensen et al, 2000).
Following on from previous work, we examined the prognosis of
Scottish patients in whom malignancy was diagnosed at the time
of, or in the 5 years after a VTE.
METHODS
The Information Services Division (ISD) of the National Health
Service in Scotland contains linked, anonymised information
(using probability matching) on all Scottish hospital in-patient
discharges, death records and cancer registry records from 1981 to
2005. For this study, all records with a diagnosis of DVT or
pulmonary embolism between 1982 and 2000 were selected from
the linked, non-identifiable database, giving a population-based
database covering 19 years.
To reduce the number of patients with secondary VTE, those
who had undergone surgery in the preceding 6 weeks were
excluded, as were pregnant women. Owing to difficulties in coding,
we were unable to exclude those with hereditary thrombophilias.
Records without a Scottish postcode were excluded.
Cancers were classified as occurring after a VTE if they
represented a first diagnosis of malignancy (excluding non-
melanomatous skin cancers) in the 5 years after a VTE.
Patients with a previous diagnosis of malignancy were excluded
to avoid cancer itself being a confounding factor for subsequent
malignancy. Cancer registrations derived solely from death
certificates were excluded because of a lack of survival informa-
tion. Follow-up for the occurrence of cancer was carried out from
the initial diagnosis of VTE until the end of 2000, allowing a 5-year
survival analysis of all cancer patients after diagnosis up to the end
of 2005.
Kaplan–Meier survival analysis was used to obtain estimates of
crude survival at 1 and 5 years after cancer diagnosis by cancer site
and timing of VTE. Multivariate Cox’s proportional hazard models
(Collett, 1994) were used to assess the impact of VTE on survival
for each cancer site separately. Adjustment was made for age
(o50, 50–59, 60–69, 70–79, 80þ years), sex, period of diagnosis
(1986–90, 1991–95, 1996–2000) and deprivation decile (Carstairs
and Morris, 1991). Patients without a VTE in the 5 years before
malignancy served as the reference group for multivariate analyses.
The end point was death from any cause.
Received 17 April 2009; revised 16 June 2009; accepted 3 July 2009;
published online 4 August 2009
*Correspondence: Dr A Jones, E-mail: annejones2000@hotmail.com
British Journal of Cancer (2009) 101, 840–842
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
yRESULTS
We identified 4322 patients diagnosed with VTE, who were then
diagnosed with a first malignancy in the subsequent 5 years. The
299714 patients diagnosed with malignancy in the same time
period, but who had not been diagnosed with a VTE in the
preceding 5 years, served as the reference group. The breakdown
of these figures by cancer site and timing of cancer diagnosis is
given in Table 1. Among those with VTE and malignancy, the most
common cancer sites overall were the lung, colon, prostate and
breast. Patients with a VTE up to 2 years before a diagnosis of
malignancy had a poorer prognosis than those without a preceding
VTE, as detailed in Table 2. Across all the cancer sites examined
and in the group as a whole, prognosis was particularly poor if the
VTE occurred at the time of, or in the 6 months before, diagnosis
of malignancy, with a hazard ratio (HR) of 2.48 (Po0.001) for all
cancers combined. Within this group, malignancies of the cervix,
uterus, pancreas, rectum and breast had the poorest prognosis
comparatively, with HRs 42.5. For all cancers combined, the HR
remained elevated at 1.21 (P¼0.002) and 1.26 (Po0.001),
respectively, for those with a VTE 6–12 months and 1–2 years
before cancer diagnosis.
DISCUSSION
This study examined the survival of over 4000 patients diagnosed
with cancer at the same time as, or in the 5 years after, a diagnosis
of VTE, and compared it with cancer patients who did not
have VTE at presentation or in the preceding 5 years. Those
diagnosed with cancer 0–6 months after a diagnosis of VTE
have a significantly poorer prognosis, and this remains so for
patients diagnosed with VTE up to 2 years before cancer diagnosis.
The crude 1-year survival for all cancers combined was 19% for
those diagnosed at the time of, or in the 6 months after, VTE.
This compares with a 54% 1-year survival for all cancers in
the reference group (data not shown). Our findings are in
keeping with earlier work showing a mortality ratio of 2.46 at
1 year if VTE and cancer were diagnosed concurrently (Sorensen
et al, 2000).
Table 1 Number of patients available for analysis according to cancer site and time period from diagnosis of VTE to diagnosis of malignancy
Number of patients according to time period from diagnosis of VTE to diagnosis of malignancy
Cancer site 0–6 months 46–12 months 41–2 years 42–5 years No VTE in 0–5 years
Oesophagus 42 21 27 8 8,697
Stomach 143 20 38 20 13,247
Colon 307 43 81 29 25,801
Rectum 69 6 37 8 12,776
Pancreas 186 15 18 7 7,284
Lung 538 107 155 72 56,779
Breast 92 39 80 24 39,262
Cervix uteri 29 4 11 2 5,305
Corpus uteri 29 2 8 5 4,479
Ovary 177 10 19 11 7,115
Prostate 163 35 92 33 19,750
Kidney 72 6 21 8 5,453
Bladder 78 16 56 9 15,275
Non-Hodgkins lymphoma 121 12 21 12 9,117
Lymphoid leukaemia 35 10 13 4 3,532
All malignancies
a 2,710 425 871 316 299,714
ICD¼International Classification of Diseases; VTE¼venous thromboembolism.
aAll malignancies within range the ICD 10 C00-C96, excluding non-melanomatous skin cancer.
Table 2 Multivariate hazard ratios according to time period for each cancer site
Multivariate hazard ratio according to time period from diagnosis of VTE to diagnosis of malignancy
Cancer site Control group 0–6 months 46–12 months 41–2 years 42–5 years
Oesophagus 1.00 2.45 (1.78–3.38)
a 2.50 (1.25–5.01)
b 0.73 (0.44–1.21) 0.84 (0.54–1.31)
Stomach 1.00 2.35 (1.98–2.79)
a 1.61 (1.02–2.52)
b 1.61 (1.04–2.50)
b 0.87 (0.61–1.23)
Colon 1.00 1.95 (1.73–2.21)
a 1.23 (0.83–1.84) 1.41 (1.01–1.98)
b 1.16 (0.91–1.47)
Rectum 1.00 2.72 (2.12–3.49)
a 1.62 (0.73–3.62) 2.60 (1.17–5.80)
b 1.08 (0.74–1.58)
Pancreas 1.00 3.23 (2.77–3.77)
a 0.97 (0.46–2.04) 0.70 (0.41–1.19) 1.36 (0.85–2.20)
Lung 1.00 1.93 (1.77–2.12)
a 1.05 (0.82–1.35) 1.08 (0.88–1.32) 0.88 (0.75–1.04)
Breast 1.00 2.61 (2.09–3.27)
a 0.86 (0.50–1.49) 1.14 (0.78–1.68) 1.18 (0.90–1.55)
Cervix uteri 1.00 4.84 (3.22–7.29)
a 4.03 (1.0–16.22)
b 1.45 (0.54–3.89) 1.44 (0.75–2.77)
Corpus uteri 1.00 3.87 (2.62–5.72)
a 1.38 (0.44–4.33) 0.43 (0.06–3.06) 2.51 (0.94–6.73)
Ovary 1.00 2.34 (1.99–2.75)
a 1.30 (0.72–2.36) 1.22 (0.55–2.72) 1.17 (0.70–1.95)
Prostate 1.00 2.07 (1.75–2.45)
a 1.14 (0.78–1.66) 0.71 (0.45–1.09) 1.46 (1.17–1.83)
a
Kidney 1.00 2.00 (1.55–2.57)
a 0.94 (0.47–1.89) 1.13 (0.42–3.03) 2.07 (1.32–3.26)
a
Bladder 1.00 2.24 (1.74–2.88)
a 1.40 (0.67–2.93) 1.39 (0.81–2.40) 1.12 (0.82–1.52)
Non-Hodgkins lymphoma 1.00 2.09 (1.72–2.54)
a 1.36 (0.70–2.61) 1.24 (0.62–2.48) 1.07 (0.65–1.75)
Lymphoid leukaemia 1.00 1.61 (1.12–2.29)
b 1.20 (0.45–3.20) 1.04 (0.54–2.01) 0.89 (0.49–1.62)
All malignancies
c 1.00 2.48 (2.38–2.58) Po0.001 1.21 (1.07–1.37) P¼0.002 1.26 (1.13–1.40) Po0.001 1.07 (0.99–1.15) P¼0.079
ICD¼International Classification of Diseases; VTE¼venous thromboembolism. Results quoted are hazard ratios with 95% lower and upper confidence intervals in brackets.
aIndicates a P-value of o0.001.
bIndicates a P-value of p0.05.
cAll malignancies within the range ICD 10 C00-C96, excluding non-melanomatous skin cancer.
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only began collecting for a limited number of cancers in 1997 and
which were insufficient for analysis. Therefore, we cannot
comment on the prevalence of metastatic disease at presentation,
and the poor prognosis observed in those with VTE at this time
or in the preceding 6 months may reflect a later stage at diagnosis.
In a previous study, Sorensen et al did not match for stage, but
did have staging data. They found a prevalence ratio of 1.26
for metastases in those diagnosed with VTE and malignancy
concurrently, compared with controls (Sorensen et al, 2000). It is
therefore likely that the extent of cancer at presentation, as
measured by traditional staging methods, does not fully explain
the poorer prognosis of these patients.
Morbidity and mortality directly caused by VTE itself are
unlikely to be solely responsible, particularly as the prognosis
remains poor for malignancies diagnosed up to 2 years after VTE.
A complex interaction between coagulation and tumour cell
biology exists and there is a growing understanding of the
potential role of coagulation pathways in modulating tumour
growth (Nash et al, 2001; Rickles et al, 2003; Prandoni et al, 2005).
However, it is not clear whether hypercoagulability itself predis-
poses to more aggressive cancer, or whether it is simply an early
manifestation of such a disease. The former possibility suggests a
potential for modulating tumour growth using agents acting upon
the coagulation cascade.
This is a retrospective study and as such relies on the accuracy
of the databases. The accuracy of discharge coding in Scotland is
estimated at B90% (ISD Scotland, 2007); the quality of cancer
registry data is also high (Brewster et al, 2002) with mismatches in
the linkage system occurring in o2% of cases (Kendrick and
Clarke, 1993).
This study provides evidence that, for all cancers combined, a
diagnosis of VTE in the 2 years before cancer diagnosis is asso-
ciated with a poorer prognosis, particularly if VTE is diagnosed
concurrently or in the 6 months before cancer diagnosis. In view of
the poor prognosis experienced by these patients, extensive
investigation for underlying malignancy may not yield a survival
benefit, and additional studies are required to clarify this. Further
work is required into the mechanisms behind this association and
the possibility for treatment targeted at the coagulation process.
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